vimarsana.com

Page 16 - ஜோஹன்னஸ் குட்டன்பெர்க் பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New Process Helps Produce Valuable Chemicals in a Safer, Eco-Friendly Way

New Process Helps Produce Valuable Chemicals in a Safer, Eco-Friendly Way Written by AZoMFeb 1 2021 Researchers from Johannes Gutenberg University Mainz (JGU) and ETH Zurich have designed a new process to generate commodity chemicals in a relatively less dangerous way than was possible before. Professor Dr. Siegfried R. Waldvogel. Image Credit: ©: Eric Lichtenscheidt. Commodity chemicals like these represent the starting point for many products that are produced at a large scale in the chemical sector, like fertilizers, dyes and plastics, and are generally produced using bromine or chlorine gas, both of which are highly corrosive and extremely toxic. In the latest issue of the

Searching for dark matter through the fifth dimension

 E-Mail Theoretical physicists of the PRISMA+ Cluster of Excellence at Johannes Gutenberg University Mainz are working on a theory that goes beyond the Standard Model of particle physics and can answer questions where the Standard Model has to pass - for example, with respect to the hierarchies of the masses of elementary particles or the existence of dark matter. The central element of the theory is an extra dimension in spacetime. Until now, scientists have faced the problem that the predictions of their theory could not be tested experimentally. They have now overcome this problem in a publication in the current issue of the

News - Research in Germany

News 28 Jan 2021 | Source: Johannes Gutenberg University Mainz Publication in Nature is the result of 20 years of proven collaboration Joint press release of Johannes Gutenberg University Mainz and Paul Scherrer Institute PSI In experiments at the Paul Scherrer Institute PSI, an international research collaboration has measured the radius of the atomic nucleus of helium five times more precisely than ever before. With the aid of the new value, fundamental physical theories can be tested and natural constants can be determined even more precisely. For their measurements, the researchers needed muons – these particles are similar to electrons but are around 200 times heavier. PSI is the only research site in the world where enough so-called low-energy muons are produced for such experiments. Their results were published in the journal 

Size of helium nucleus measured more precisely than ever before

 E-Mail IMAGE: Aldo Antognini is happy that the long research effort yielded such an outstanding result. view more  Credit: Paul Scherrer Institute/Markus Fischer In experiments at the Paul Scherrer Institute PSI, an international research collaboration has measured the radius of the atomic nucleus of helium five times more precisely than ever before. With the aid of the new value, fundamental physical theories can be tested and natural constants can be determined even more precisely. For their measurements, the researchers needed muons - these particles are similar to electrons but are around 200 times heavier. PSI is the only research site in the world where enough so-called low-energy muons are produced for such experiments. The researchers are publishing their results today in the journal

Scientists Are Working on mRNA Vaccines for HIV, Flu, Cancer and More

Scientists Are Working on mRNA Vaccines for HIV, Flu, Cancer and More Advertisement Scientists Are Working on mRNA Vaccines for HIV, Flu, Cancer and More The technology used in COVID-19 vaccines may also be used to prevent other viral infections and to treat cancer and multiple sclerosis. Advertisement The same messenger RNA (mRNA) technology used in the Moderna and Pfizer/BioNTech coronavirus vaccines, which are around 95% effective at preventing symptomatic COVID-19, could potentially be used to prevent or treat a wide variety of other diseases. Moderna recently announced that it has started new programs to design mRNA vaccines for HIV, seasonal influenza and Nipah virus, adding to the company’s development portfolio for several other viral diseases and cancer.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.